Aktis Oncology filed for an initial public offering to raise capital for clinical development of its miniprotein radiopharmaceuticals, following partnerships and investments from Eli Lilly, Merck’s MRL Ventures and Bristol Myers Squibb. The company plans to use proceeds to fund a U.S. phase 1b study of Ac‑AKY‑1189 (targeting Nectin‑4) and a second asset for B7‑H3 tumors, with dose‑escalation readouts expected in coming quarters. The filing tests investor appetite for radiopharma names after a quiet IPO market in 2025, and positions Aktis as an early public candidate in a crowded targeted‑radiation field.